Please login to the form below

Not currently logged in
Email:
Password:

Positive results in Sanofi RA trial

Sarilumab, developed by Sanofi and Regeneron, has shown positive results for the treatment of rheumatoid arthritis in a phase IIb trial, although the drug failed to show great benefit in ankylosing spondylitis patients

Sarilumab, developed by Sanofi and Regeneron, has shown positive results in a phase IIb trial concerning the drug's safety and efficacy in treating rheumatoid arthritis, although the drug failed to show great benefit in ankylosing spondylitis (AS) patients.

According to Sanofi, the MOBILITY study, involving 306 participants, demonstrated that patients treated with sarilumab in combination with a standard RA treatment, methotrexate (MTX), achieved a significant improvement in signs and symptoms of moderate-to-severe RA compared to patients treated with MTX alone.

However, when used as a treatment for AS, significant improvement was not demonstrated when compared to placebo, although the drug was well-tolerated.

"Following these encouraging phase IIb results in rheumatoid arthritis, the companies are currently discussing the dose(s) of sarilumab to advance into the phase III portion of the MOBILITY trial," said Elias Zerhouni, president, global research & development, Sanofi.

13th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics